Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 4/20 | 0.46 |
| ▸ | PGK2 | P07205 | 4/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5987314 | 0.84 | PGK1 (0.47) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL5986554 | 0.78 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL4005577 | 0.72 | PGK1 (0.44) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL2036858 | 0.71 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL5391918 | 0.71 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL5404370 | 0.71 | PGK1 (0.42) | PGK1PGK2PTPN5PTPN1PTPN2 | |
| SCHEMBL26865350 | 0.69 | ALDH1A1 (0.42) | — | |
| SCHEMBL6549465 | 0.68 | ALDH1A1 (0.37) | — | |
| SCHEMBL14314945 | 0.68 | ALDH1A1 (0.44) | — | |
| SCHEMBL4008292 | 0.67 | PGK1 (0.49) | PGK1PGK2PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | PGK1 1901/4885PGK2 1459/4885PTPN5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.